Abstract
Background The characterisation of the peripheral immune system in the autoimmune disease systemic lupus erythematosus (SLE) at the single-cell level has been hampered by the reduced sensitivity of current whole-transcriptomic technologies. Here we employ a targeted single-cell multi-omics approach, combining protein and mRNA quantification, to generate a high-resolution map of the T lymphocyte and Natural Killer (NK) cell populations in blood from SLE patients.
Methods We designed a custom panel to quantify the transcription of 534 genes in parallel with the expression of 51 surface protein targets using the BD Rhapsody single-cell system. We applied this technology to profile 20,656 T and NK cells isolated from peripheral blood from an SLE patient with a type I interferon (IFN) signature (IFNhi), and an age- and sex-matched IFNlow SLE patient and healthy donor.
Results We confirmed the presence of a rare cytotoxic CD4+ T cell (CTL) subset, which was exclusively present in the IFNhi patient. Furthermore, we identified additional alterations consistent with increased immune activation in this patient, most notably a shift towards terminally differentiated CD57+ CD8+ T cell and CD16+ NKdim phenotypes, and the presence of a subset of naïve CD4+ T cells recently activated by cytokines.
Conclusions Our results identify IFN-driven changes in the composition and phenotype of T and NK cells that are consistent with a systemic immune activation within the IFNhi patient, and underscore the power of this multi-omics approach to identify rare immune subsets, which could be missed using lower parametric or less sensitive single-cell technologies. Consequently, we were able to find evidence for novel cellular peripheral biomarkers of SLE disease activity, including a subset of CD57+ CD4+ CTLs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a strategic award to the Diabetes and Inflammation Laboratory from the JDRF (4-SRA-2017-473-A-A) and the Wellcome (107212/A/15/Z), and a grant from the JDRF (1-SRA-2019-657-A-N).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study conformed to the principles of the Helsinki Declaration and was approved by the local Peterborough and Fenland research ethics committee (05/Q0106/20)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† Co-senior authors:
Data Availability
Extended data, including processed single-cell RNA-sequencing data, are available from Open Science Framework (OSF): https://doi.org/10.17605/OSF.IO/EDCTN12. This project contains the following extended data: Dataset S1: Processed gene expression data matrixes (mRNA and AbSeq UMI counts per cell) and sample tag assignment per cell for the resting and stimulated datasets. Dataset S2: Differentially expressed genes in the resting cell clusters. Dataset S3: Differentially expressed genes in resting CD4+ CTLs (cluster 10 from the resting analysis) compared to remaining CD4+ T cell clusters. Dataset S4: Differentially expressed genes in the in vitro stimulated cell clusters. Dataset S5: Differentially expressed genes in the integrated resting and in vitro stimulated cell clusters. Dataset S6: Differentially expressed genes between the CD16+ NKdim cells in clusters 7 and 8 from the integrated analysis. Dataset S7: Differentially expressed genes in CD4+ naive T cells (cluster 1 from the integrated analysis) between the IFNhi SLE patient and the two IFNlow control donors.
Abbreviations
- CTL
- cytotoxic T lymphocyte
- FACS
- fluorescence-activated cell sorting
- IFN
- type I interferon
- ISG
- type I interferon stimulated gene
- NK
- Natural Killer
- PMA
- phorbol 12-myristate 13-acetate
- scRNA-seq
- single-cell RNA-sequencing
- SLE
- systemic lupus erythematosus
- T1D
- type 1 diabetes
- Tcm
- central memory T cell
- Teff
- effector T cell
- Tem
- effector memory T cell
- TEMRA
- terminally differentiated effector memory T cell
- Tfh
- follicular helper T cell
- Treg
- regulatory T cell
- UMAP
- Uniform Manifold Approximation and Projection
- UMI
- unique molecular identifier.